Burhan FerhanoÄKu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4434328/publications.pdf

Version: 2024-02-01

| 51 | 1,041 | 14 | 31 |
|----------|----------------|--------------|----------------|
| papers | citations | h-index | g-index |
| 51 | 51 | 51 | 1725 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy, 2022, 34, 190-198. | 1.5 | 7 |
| 2 | Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study. Archives of Medical Science, 2021, 17, 920-927. | 0.9 | O |
| 3 | Brentuximab vedotin consolidation therapy after autologous stemâ€cell transplantation in patients with highâ€risk Hodgkin lymphoma: Multicenter retrospective study. Hematological Oncology, 2021, 39, 498-505. | 1.7 | 12 |
| 4 | Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data. Turkish Journal of Haematology, 2021, 38, 273-285. | 0.5 | 2 |
| 5 | COVID-19 infection in patients with acute leukemia; Istanbul experience. American Journal of Blood Research, 2021, 11, 427-437. | 0.6 | 5 |
| 6 | Concomittant occurence of well-differentiated thyroid carcinoma metastasis and chronic lymphocytic leukemia in the same lymph node along with internal jugular vein thrombus: a case report. Indian Journal of Pathology and Microbiology, 2021, 64, 149-151. | 0.2 | 0 |
| 7 | Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Annals of Hematology, 2020, 99, 301-307. | 1.8 | 4 |
| 8 | Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Hematology, 2020, 99, 2565-2576. | 1.8 | 19 |
| 9 | -Rearranged Large B-Cell Lymphoma on Waldeyer's Ring: A Case Report. Turkish Journal of Haematology, 2020, 37, 292-294. | 0.2 | O |
| 10 | Bortezomib induced pulmonary toxicity: a case report and review of the literature. American Journal of Blood Research, 2020, 10, 407-415. | 0.6 | 1 |
| 11 | IRF4-Rearranged Large B-Cell Lymphoma on Waldeyer's Ring: A Case Report. Turkish Journal of Haematology, 2020, 37, 292-294. | 0.5 | 1 |
| 12 | The role of atopy in the pathogenesis of bleomycin pulmonary toxicity. Respiratory Medicine, 2019, 155, 1-5. | 2.9 | 4 |
| 13 | Implementation of an antimicrobial stewardship program for patients with febrile neutropenia. American Journal of Infection Control, 2018, 46, 420-424. | 2.3 | 17 |
| 14 | Recognizing Pinch Purpura As The First Manifestation Of AL Amyloidosis. Turkish Journal of Haematology, 2018, 35, 208-209. | 0.5 | 0 |
| 15 | Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma. Leukemia and Lymphoma, 2017, 58, 1114-1122. | 1.3 | 14 |
| 16 | Inflammatory myofibroblastic tumor mimicking a relapse in a patient with Hodgkin's lymphoma: report of an unusual case and review of the literature. Clinical Case Reports (discontinued), 2017, 5, 945-949. | 0.5 | 4 |
| 17 | Rituximab desensitization in three patients with severe rituximab allergy. Current Problems in Cancer, 2017, 41, 349-354. | 2.0 | 5 |
| 18 | Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Annals of Oncology, 2017, 28, 2496-2502. | 1.2 | 60 |

| # | Article | IF | Citations |
|----|---|------|-----------|
| 19 | The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients. Turkish Journal of Haematology, 2016, 33, 216-222. | 0.5 | 14 |
| 20 | Hematopoietic cell transplantation activity of Turkey in 2014: Ongoing increase in HCT rates. Transfusion and Apheresis Science, 2016, 54, 53-59. | 1.0 | 4 |
| 21 | Azacitidine versus decitabine in patients with refractory anemia with excess blastâ€"Results of multicenter study. Leukemia Research, 2016, 45, 82-89. | 0.8 | 14 |
| 22 | Complete Remission of Burkitt Lymphoma After Surgical Excision: A Case Report. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 178-180. | 0.6 | 2 |
| 23 | Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. Journal of Clinical Pathology, 2016, 69, 810-816. | 2.0 | 5 |
| 24 | Comparison of International Prognostic Index and NCCN-IPI in 324 patients with <i>de novo </i> diffuse large B-cell lymphoma: a multi-center retrospective analysis. Leukemia and Lymphoma, 2016, 57, 1211-1214. | 1.3 | 6 |
| 25 | Early Changes of Mannose-Binding Lectin, H-Ficolin, and Procalcitonin in Patients with Febrile Neutropenia: A Prospective Observational Study. Turkish Journal of Haematology, 2016, 33, 304-310. | 0.5 | 5 |
| 26 | Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood, 2015, 126, 1893-1901. | 1.4 | 117 |
| 27 | Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode. Turkish Journal of Haematology, 2015, 32, 243-250. | 0.5 | 9 |
| 28 | Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish Journal of Haematology, 2014, 31, 374-380. | 0.5 | 3 |
| 29 | Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leukemia Research, 2014, 38, 781-787. | 0.8 | 33 |
| 30 | Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 424-435. | 10.7 | 304 |
| 31 | Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature. Rheumatology, 2014, 53, 1136-1141. | 1.9 | 37 |
| 32 | Diagnostic contribution of 18F-FDG-PET/CT in fever of unknown origin. International Journal of Infectious Diseases, 2014, 19, 53-58. | 3.3 | 61 |
| 33 | Cyclosporin <scp>A</scp> therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. Transfusion, 2013, 53, 1586-1593. | 1.6 | 14 |
| 34 | Is valganciclovir really effective in primary effusion lymphoma: case report of an <scp>HIV</scp> (â^') <scp>EBV</scp> (â^') <scp>HHV</scp> 8(+) patient. European Journal of Haematology, 2013, 91, 467-469. | 2.2 | 15 |
| 35 | The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2012, 29, 242-247. | 0.5 | O |
| 36 | Azacitidine has limited activity in â€~real life' patients with MDS and AML: a single centre experience. Hematological Oncology, 2012, 30, 76-81. | 1.7 | 21 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 442-445. | 0.4 | 12 |
| 38 | Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?. Leukemia Research, 2011, 35, e145-e146. | 0.8 | 3 |
| 39 | Primary Gastrointestinal Diffuse Large B Cell Lymphoma Presenting with Cold Agglutinin Disease. Case Reports in Gastroenterology, 2011, 5, 262-266. | 0.6 | 9 |
| 40 | Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica, 2011, 96, e15-e15. | 3.5 | 25 |
| 41 | Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient. Journal of NeuroVirology, 2010, 16, 174-178. | 2.1 | 9 |
| 42 | Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. Journal of Medical Case Reports, 2009, 3, 7306. | 0.8 | 8 |
| 43 | TheSOCS-1 gene methylation in chronic myeloid leukemia patients. American Journal of Hematology, 2007, 82, 729-730. | 4.1 | 32 |
| 44 | Alemtuzumab in Sézary syndrome: efficient but not innocent. European Journal of Dermatology, 2007, 17, 525-9. | 0.6 | 10 |
| 45 | T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leukemia Research, 2004, 28, 229-236. | 0.8 | 40 |
| 46 | Chronic Lymphocytic Leukemia in Turkey: Experience of a Single Center in Istanbul. Southern Medical Journal, 2004, 97, 240-245. | 0.7 | 11 |
| 47 | An overview of young CLL patients: a single-centre experience from Turkey. Haematologia, 2001, 31, 303-311. | 0.3 | 7 |
| 48 | Does tissue iron status have a role in female alopecia?. Journal of the European Academy of Dermatology and Venereology, 1999, 13, 65-67. | 2.4 | 35 |
| 49 | Donor Leukocyte Infusions for Acute Myeloid Leukemia Relapsing after Stem Cell Transplantation. Acta Haematologica, 1998, 99, 49-51. | 1.4 | 0 |
| 50 | Idiopathic myelofibrosis (agnogenic myeloid metaplasia): Clinicopathological analysis of 32 patients. Leukemia Research, 1997, 21, 125-131. | 0.8 | 11 |
| 51 | Secondary amyloidosis in the course of idiopathic myelofibrosis. Leukemia Research, 1997, 21, 897-898. | 0.8 | 10 |